TABLE 1.
Activities of compounds against WT and CDV-R poxviruses, as determined by plaque reduction assays in Vero 76 cells
| Virus strain | EC50 (μM)a of:
|
|||||
|---|---|---|---|---|---|---|
| MPA | Ribavirin | C-c3Ado | Cidofovir | Cyclic HPMPC | HPMPA | |
| Camelpox-WT | 2.5 ± 0.5 | 290 ± 36 | 39 ± 1.2 | 2.3 ± 0.5 | 2.2 ± 0.5 | 0.5 ± 0.2 |
| Camelpox-R | 2.4 ± 0.1 | 215 ± 28 | 20 ± 2.6 | 22 ± 5 (10) | 19 ± 3.6 (9) | 12 ± 3.3 (24) |
| Cowpox-WT | 3.2 ± 0.5 | 625 ± 165 | >1,000 | 45 ± 7 | 57 ± 4.2 | 4.2 ± 0.6 |
| Cowpox-WT (SF) | 3.2 ± 0.2 | 605 ± 75 | >1,000 | 58 ± 13 | 47 ± 16 | 4.6 ± 0.8 |
| Cowpox-R | 3.3 ± 1.1 | 430 ± 80 | >1,000 | >1,000 (>22) | >1,000 (>18) | >400 (>95) |
| Cowpox-R (SF) | 3.7 ± 0.2 | 640 ± 95 | >1,000 | 730 ± 160 (16) | >1,000 (>18) | 330 ± 65 (79) |
| Monkeypox-WT | 2.5 ± 1.3 | 96 ± 19 | 4.5 ± 2.5 | 27 ± 11 | 34 ± 25 | 3.7 ± 1.3 |
| Monkeypox-R | 1.9 ± 0.2 | 140 ± 25 | 4.2 ± 1.8 | 505 ± 50 (19) | 760 ± 340 (22) | 68 ± 18 (18) |
| Monkeypox-R (SF) | 1.0 ± 0.1 | 145 ± 28 | 5.5 ± 2.1 | 725 ± 105 (27) | 850 ± 210 (25) | 80 ± 40 (22) |
| Vaccinia-WT | 0.4 ± 0.3 | 21 ± 6 | 20 ± 8 | 19 ± 6 | 21 ± 9 | 3.4 ± 0.7 |
| Vaccinia-R | 1.0 ± 0.5 | 97 ± 31 (5) | 9 ± 1.4 | 150 ± 36 (8) | 185 ± 105 (9) | 8 ± 1.7 |
a
Values are means of three separate determinations ± standard deviations. The numbers in parentheses refer to the n-fold change in potency (the EC50 against the resistant virus divided by the EC50 against the parental WT virus).